Drug Trial Radar · NCT03040973
Study to Allow Patients Previously Participating in a Novartis Sponsored Trial to Continue Receiving Capmatinib Treatment as Single Agent or in Combination With Other Treatments or the Combination Treatment Alone
Last checked: Nov 20, 2026Latest source record: Sep 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
29
Actual
Start
Jul 4, 2017
Primary completion
Jul 30, 2027
Study completion Jul 30, 2027
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Feb 2, 2017
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 100 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess long-term safety and provide continued study treatment access to eligible participants who are judged by the Investigator to benefit from continued treatment with capmatinib monotherapy or in combination with other treatments or with the combination treatment alone in a Novartis sponsored study
Conditions
- Advanced Solid Tumors Which Are cMET-dependent
Interventions
CapmatinibDrug
Tablet for oral use; 150 mg, 200 mg; twice a day
NazartinibDrug
Capsule for oral use; 25 mg, 50 mg; once a day
GefitinibDrug
tablets for oral use; 250mg; once a day
OsimertinibDrug
Tablets for oral use; 40 mg, 80 mg; once a day.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants with Adverse Events as a Measure of Safety and TolerabilityTime frame: Day 1 up to 10 years, assessed every 12 weeks
Locations
15 sites in 11 countries. Site status is shown where the registry gives one.
Massachusetts General Hospital
Boston, Massachusetts
Novartis Investigative Site
Leuven, Belgium
Novartis Investigative Site
Edmonton, Alberta, Canada
Novartis Investigative Site
Shanghai, Shanghai Municipality, China
Novartis Investigative Site
Kunming, Yunnan, China
Novartis Investigative Site
Copenhagen, Denmark
Novartis Investigative Site
Dijon, Cote D Or, France
Novartis Investigative Site
Hanover, Germany
Novartis Investigative Site
Cologne, North Rhine-Westphalia, Germany
Novartis Investigative Site
Milan, MI, Italy
Novartis Investigative Site
Perugia, PG, Italy
Novartis Investigative Site
Singapore, Singapore
Novartis Investigative Site
Seoul, South Korea
Novartis Investigative Site
Seoul, South Korea
Novartis Investigative Site
Madrid, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.